Winslow Evans & Crocker Inc. held its stake in bluebird bio, Inc. (NASDAQ:BLUE) during the second quarter, Holdings Channel reports. The firm owned 2,900 shares of the biotechnology company’s stock at the end of the second quarter. Winslow Evans & Crocker Inc.’s holdings in bluebird bio were worth $305,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. FMR LLC increased its stake in bluebird bio by 0.6% in the first quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock valued at $556,918,000 after buying an additional 37,742 shares during the period. Baillie Gifford & Co. increased its stake in bluebird bio by 0.8% in the first quarter. Baillie Gifford & Co. now owns 5,204,633 shares of the biotechnology company’s stock valued at $473,102,000 after buying an additional 40,166 shares during the period. Vanguard Group Inc. increased its stake in bluebird bio by 4.6% in the first quarter. Vanguard Group Inc. now owns 3,215,246 shares of the biotechnology company’s stock valued at $292,266,000 after buying an additional 141,293 shares during the period. BlackRock Inc. increased its stake in bluebird bio by 44,948.0% in the first quarter. BlackRock Inc. now owns 3,182,188 shares of the biotechnology company’s stock valued at $289,259,000 after buying an additional 3,175,124 shares during the period. Finally, State Street Corp increased its stake in bluebird bio by 3.7% in the first quarter. State Street Corp now owns 1,611,032 shares of the biotechnology company’s stock valued at $146,443,000 after buying an additional 58,228 shares during the period.

bluebird bio, Inc. (NASDAQ:BLUE) opened at 95.80 on Monday. The firm has a 50-day moving average price of $97.43 and a 200 day moving average price of $83.86. The stock’s market cap is $3.92 billion. bluebird bio, Inc. has a 1-year low of $37.05 and a 1-year high of $123.75.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.68) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.76) by $0.08. bluebird bio had a negative return on equity of 35.17% and a negative net margin of 2,402.03%. The company had revenue of $6.83 million for the quarter, compared to the consensus estimate of $1.51 million. On average, equities research analysts anticipate that bluebird bio, Inc. will post ($6.70) EPS for the current fiscal year.

WARNING: “bluebird bio, Inc. (NASDAQ:BLUE) Stake Maintained by Winslow Evans & Crocker Inc.” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/bluebird-bio-inc-nasdaqblue-stake-maintained-by-winslow-evans-crocker-inc/1444909.html.

Several analysts have recently weighed in on BLUE shares. Zacks Investment Research downgraded bluebird bio from a “hold” rating to a “sell” rating in a research report on Tuesday, April 25th. BTIG Research downgraded bluebird bio from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $37.05 to $108.25 in a research report on Friday, June 30th. Wedbush reiterated an “outperform” rating and set a $100.00 target price (down from $121.00) on shares of bluebird bio in a research report on Friday, June 23rd. Cowen and Company reiterated an “outperform” rating on shares of bluebird bio in a research report on Friday, June 9th. Finally, BidaskClub upgraded bluebird bio from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $100.02.

In other news, Director Daniel Lynch sold 1,000 shares of the stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $90.01, for a total value of $90,010.00. Following the transaction, the director now owns 2,400 shares in the company, valued at approximately $216,024. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Philip D. Gregory sold 1,500 shares of the stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $99.04, for a total value of $148,560.00. Following the completion of the transaction, the insider now owns 37,279 shares in the company, valued at approximately $3,692,112.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 76,245 shares of company stock worth $7,924,508. 3.90% of the stock is owned by company insiders.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.